Janux Therapeutics (JANX) EBIT Margin (2021 - 2026)
Janux Therapeutics' EBIT Margin was -308.66% in Q2 2026, up 607.84 percentage points from the prior quarter.
Powered by 
Analysis
Janux Therapeutics (JANX) EBIT Margin (2021 - 2026) Analysis & Trends
On a trailing twelve-month basis, Janux Therapeutics' EBIT Margin was -598.15% through Jun 30, 2026, up 32403.90 percentage points year-over-year; for FY2025, it was -1576.67%, down 643.09 percentage points from FY2024.
- EBIT Margin has now declined for three consecutive years, with a four-year change of -671.28 percentage points (FY2021 to FY2025).
- In earlier years, EBIT Margin was -933.58% in FY2024 (-30.71 pp), -902.87% in FY2023 (-123.83 pp), -779.04% in FY2022 (+126.35 pp) and -905.39% in FY2021.
- The Q2 2026 figure marks the highest quarterly EBIT Margin since Q2 2024.
- The best year-over-year quarter for EBIT Margin over five years was Q3 2025 (a gain of 7811.95 percentage points); the worst was Q3 2024 (a drop of 7536.22 percentage points).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 32.97% |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 20.57% |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 34.95% |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | -133.21% |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 28.37% |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 37.40% |
| 10 | Janux Therapeutics | 1.06 Bn | 1.06 Bn | - | -308.66% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -308.66% |
| Mar 31, 2026 | -916.50% |
| Sep 30, 2025 | -352.51% |
| Sep 30, 2024 | -8,164.46% |
| Jun 30, 2024 | -155.36% |
| Mar 31, 2024 | -1,610.30% |
| Dec 31, 2023 | -655.71% |
| Sep 30, 2023 | -628.25% |
| Jun 30, 2023 | -1,962.91% |
| Mar 31, 2023 | -990.28% |
| Dec 31, 2022 | -642.04% |
| Sep 30, 2022 | -994.04% |
| Jun 30, 2022 | -729.85% |
| Mar 31, 2022 | -852.23% |
| Dec 31, 2021 | -834.78% |
| Sep 30, 2021 | -940.72% |
| Jun 30, 2021 | -1,297.10% |
| Mar 31, 2021 | -601.05% |
API Access
Janux Therapeutics EBIT Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebit-margin&ticker=JANX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebit-margin", "ticker": "JANX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebit-margin&ticker=JANX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();